Rezaei Mitra, Mohajerani Hassan, Moslemi Hamidreza, Shafiei Shervin, Tabrizi Mohammad Amir Alizadeh, Tabrizi Reza
Department of Pathology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Virology Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ann Maxillofac Surg. 2021 Jan-Jun;11(1):17-20. doi: 10.4103/ams.ams_321_20. Epub 2021 Jul 24.
P16 is an independent and reliable surrogate for the detection of human papillomavirus (HPV) in oral squamous cell carcinoma (OSCC). The aim of this study was to assess the P16 expression as a marker for HPV infection in OSCC and its impact on the treatment outcome.
A cross-sectional study was conducted on patients with a definite diagnosis of OSCC. Patients were assigned into two groups with and without recurrence or metastasis. Tumour resection was performed in the same manner for all patients. P16 expression was evaluated by immunohistochemical staining. Independent -test and Chi-square tests were used to find significant differences in age, gender, stage of the disease, tumour size, lymph node involvement, and P16 expression between the two groups.
Of 50 patients, 37 did not show any recurrence or metastasis (group 1), while 13 had a relapse (group 2). There was no significant difference for age, gender distribution, stage of the disease, or lymph node involvement between the two groups ( > 0.05). A significant difference in tumour size was noted between the two groups ( = 0.001). The mean expression of P16 was 38.92 ± 24.36 in group 1 and 51.54 ± 33.63 in group 2. No significant difference was found between the two groups for the mean expression of P16 ( = 0.23).
A review of the recent literature revealed that the HPV role in OSCC treatment is controversial. According to the results of this study, there was no significant difference in terms of P16 expression between OSCC patients with and without recurrence or metastasis.
P16是检测口腔鳞状细胞癌（OSCC）中人类乳头瘤病毒（HPV）的一个独立且可靠的替代指标。本研究的目的是评估P16表达作为OSCC中HPV感染的标志物及其对治疗结果的影响。
对确诊为OSCC的患者进行了一项横断面研究。将患者分为有复发或转移和无复发或转移两组。所有患者均以相同方式进行肿瘤切除。通过免疫组织化学染色评估P16表达。采用独立样本t检验和卡方检验来发现两组在年龄、性别、疾病分期、肿瘤大小、淋巴结受累情况及P16表达方面的显著差异。
50例患者中，37例未出现任何复发或转移（第1组），而13例出现复发（第2组）。两组在年龄、性别分布、疾病分期或淋巴结受累情况方面无显著差异（P>0.05）。两组在肿瘤大小方面存在显著差异（P = 0.001）。第1组P16的平均表达为38.92±24.36，第2组为51.54±33.63。两组在P16的平均表达方面未发现显著差异（P = 0.23）。
对近期文献的回顾显示，HPV在OSCC治疗中的作用存在争议。根据本研究结果，有复发或转移与无复发或转移的OSCC患者在P16表达方面无显著差异。
